The Life Sciences team advised Generate Biomedicines, Inc. (“Generate”) on the closing of its initial public offering of 25,000,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds from the offering were $400 million before deducting underwriting discounts, commissions, and offering expenses. All of the shares of common stock were offered by Generate. Generate’s common stock began trading on the Nasdaq Global Select Market on February 27, 2026, under the ticker symbol “GENB.” The offering closed on March 2, 2026.
Generate is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Generate’s vision is to program biology to generate optimal therapeutics for the greatest impact on human health. Central to Generate’s vision is the Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate was founded in 2018 by Flagship Pioneering, bringing together advancements in generative biology and computational protein science.
The Goodwin team was led by Stuart Cable, Joe Theis, Stephanie Richards, and Janet Hsueh and included Eunice Chang, Sofia Wyman, Carrie Clowney, and Keerthi Adusumilli.
For more information on the deal, please read the press release.